RMD · ResMed Inc.
$200.292026-07-21Sector: Healthcare; Industry: Medical - Devices; Sub-Industry: Health Care Equipment
Intrinsic Value Range Comparison · Mulya.ai
R&D capitalized (5yr)Base · active
$260
+29.9% vs market
Mulya.ai vs Analyst IV Comparison?
Mulya.ai IV range ($161 · $282) Analysts Range ($225 · $314) Fundamentals · historical + forward · baseitalics = DCF projection
| Period | Revenue | Rev Gr ? | Ops M% ? | Tax Rate ? | NOPAT ? | Reinvest ? | FCFF ? | WACC% ? | PV FCFF ? | ROIC ? | Inv. Cap ? | EPS ? | P/E |
|---|
| 2024.Q3 | $4.2B | — | 28.0% | 19.0% | $957MM | −$139MM | $818MM | 7.5% | — | 15.3% | $6.3B | $6.10 | — |
| 2025.Q2 | $4.7B | 10.9% | 29.4% | 18.6% | $1.1B | $127MM | $1.2B | 8.7% | — | 17.8% | $6.3B | $6.94 | — |
| 2025.Q3 | $4.7B | 0.0% | 29.4% | 16.7% | $1.1B | $218MM | $1.4B | 7.9% | — | 18.3% | $6.2B | $6.94 | — |
| 2026.Q2 | $5.1B | 9.8% | 34.2% | 18.3% | $1.4B | −$78MM | $1.4B | 8.3% | — | 22.3% | $6.7B | $9.53 | — |
| 2026.Q3 | $5.5B | 7.6% | 35.8% | 20.2% | $1.6B | −$124MM | $1.5B | 7.7% | — | 24.0% | $6.5B | $10.33 | 14.9 |
| italics below = DCF projection · 10yr Rev CAGR: 7.5% |
| 2027.Q3 | $6.0B | +8.4% | 34.3% | 20.1% | $1.6B | −$62MM | $1.6B | 7.7% | $1.5B | 25.2% | $6.5B | $10.71 | 18.7 |
| 2028.Q3 | $6.4B | +7.0% | 34.3% | 20.1% | $1.8B | −$62MM | $1.7B | 7.8% | $1.5B | 26.8% | $6.6B | $11.46 | 17.5 |
| 2029.Q3 | $6.9B | +7.5% | 34.3% | 20.1% | $1.9B | −$79MM | $1.8B | 7.9% | $1.4B | 28.5% | $6.7B | $12.33 | 16.2 |
| 2030.Q3 | $7.6B | +9.6% | 34.3% | 20.1% | $2.1B | −$122MM | $2.0B | 8.0% | $1.4B | 30.8% | $6.8B | $13.52 | 14.8 |
| 2031.Q3 | $8.3B | +10.0% | 34.3% | 20.1% | $2.3B | −$160MM | $2.1B | 8.1% | $1.5B | 33.2% | $7.0B | $14.88 | 13.5 |
|
| Term. Yr+ | $11.9B | 4.1% | 28.4% | 20.0% | $2.7B | −$469MM | $2.2B | 8.6% | $22.7B | 23.6% | — | — | — |
Active scenario IV: $260 (+29.9% vs market)